文献速递支持与姑息治疗

早期免疫治疗试验中剂量限制性毒性评估中的迟发性免疫相关不良事件

Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials.
PubMed 文献 · Eur J Cancer · 2018-12-07

回顾性分析2012年8月至2016年9月玛格丽特公主癌症中心21项早期免疫治疗试验的352例连续入组患者,采用试验特定剂量限制性毒性定义。结果显示首次临床显著不良事件风险在治疗前4周最高,联合免疫治疗较单药发生更早,但5.7%患者出现迟发性剂量限制性毒性。

要点

  • 352例早期免疫治疗试验入组患者中,278例(79%)接受单药,74例(21%)接受联合免疫治疗。
  • 20例(5.7%)患者发生24例次临床显著迟发性剂量限制性毒性。
  • 联合免疫治疗较单药首次临床显著不良事件发生更早(32天 vs 146天,P<0.001)。

核心结论

  • 在本系列早期免疫治疗试验中,临床显著不良事件风险在治疗初始4周最高,支持采用常规剂量限制性毒性观察期进行剂量递增决策。
  • 但5.7%患者出现24例次临床显著迟发性剂量限制性毒性。
  • 联合免疫治疗与临床显著不良事件更高风险和更早发生相关,早期试验设计可能需要考虑这一点。

研究设计与样本

  • 回顾性分析2012年8月至2016年9月在玛格丽特公主癌症中心连续入组早期免疫治疗试验的患者,采用试验特定剂量限制性毒性定义。
  • 共纳入21项早期临床试验的352例连续入组患者。
  • 278例(79%)接受单药免疫治疗,74例(21%)接受联合免疫治疗。
  • 临床显著不良事件定义为需要皮质类固醇、激素替代、免疫治疗延迟或终止的治疗相关不良事件。

主要发现

  • 260例(74%)患者发生免疫相关不良事件。
  • 共有2例方案定义的剂量限制性毒性。
  • 20例(5.7%)患者发生24例次临床显著不良事件,符合剂量限制性毒性定义但发生于方案规定剂量限制性毒性观察期之后。
  • 免疫相关不良事件中106例(10%)为临床显著不良事件,包括内分泌(26%)、呼吸(14%)、胃肠(11%)、全身(10%)、皮肤(8%)、肝脏(8%)、肌肉骨骼(6%)、胰腺(6%)、血液、代谢、神经、心脏(各2%)、感染和眼部(各1%)事件。
  • 首次临床显著不良事件最高风险在治疗前4周,与4周至治疗结束期间相比,比值比为3.13(95%置信区间1.95-5.02)。

关键数值与推荐

  • 临床显著不良事件定义为需要皮质类固醇、激素替代、免疫治疗延迟或终止的治疗相关不良事件。
  • 首次临床显著不良事件风险前4周 vs 4周至治疗结束:比值比3.13(95%置信区间1.95-5.02)。
  • 联合免疫治疗 vs 单药首次临床显著不良事件中位时间:32天 vs 146天(P<0.001)。

临床怎么用

  • 原文结论支持采用常规剂量限制性毒性观察期进行剂量递增决策。
  • 作者认为联合免疫治疗与临床显著不良事件更高风险和更早发生相关,早期试验设计可能需要考虑这一点。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immunotherapy (IO) agents can cause late-onset immune-related adverse events (irAEs). In phase I trials, observation for dose-limiting toxicities (DLTs) is typically limited to the first cycle. The incidence of delayed-onset DLTs and their potential impact on dose determination have not been fully elucidated. PATIENTS AND METHODS: Consecutive patients enrolled in early phase IO trials at Princess Margaret Cancer Centre between August 2012 and September 2016 were retrospectively reviewed, applying trial-specific definitions for DLTs. A clinically significant AE (csAE) was defined as a treatment-related adverse event requiring corticosteroids, hormone replacement, IO delay or discontinuation. RESULTS: A total of 352 consecutive trial enrolments in 21 early phase clinical trials were included. Two-hundred seventy-eight patients (79%) received monotherapy and 74 (21%) received combination IO. Two hundred sixty (74%) patients experienced irAEs. There were two protocol-defined DLTs. Twenty (5.7%) patients had 24 csAEs qualifying as DLTs except for occurrence after the protocol-specified DLT period. One-hundred and six (10%) of irAEs were csAEs, including endocrine (26%), respiratory (14%), gastrointestinal (11%), general (10%), dermatological (8%), hepatic (8%), musculoskeletal (6%), pancreatic (6%), haematological, metabolic, neurological, cardiac (each 2%), infective and ocular (each 1%) events. The highest risk of first-onset csAE was during the first 4 weeks compared with the period from 4 weeks to end of treatment (odds ratio 3.13, 95% confidence interval 1.95-5.02). The median time to first onset csAE was significantly shorter with combination than monotherapy IO (32 vs. 146 days, P < 0.001). CONCLUSIONS: In our series of early phase IO trials, the risk of csAE was highest during the initial 4 weeks on IO treatment, supporting the use of the conventional DLT period for dose escalation decision. However, there were 24 clinically significant late-onset DLTs in 5.7% of patients. Combination IO was associated with greater risk of and also earlier onset for csAE, which may need to be considered for early phase trial design.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Kanjanapan Y, Day D, Butler MO, et al. Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials. Eur J Cancer. 2018. PMID: 30529898. doi:10.1016/j.ejca.2018.10.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。